Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit


FDA Approves Imvexxy for Treatment of Post-Menopausal Pain

FDA Approves Imvexxy for Treatment of Post-Menopausal PainStarting this month, post-menopausal women could have a new treatment option for painful intercourse.  

In May 2018, the U.S. Food and Drug Administration (FDA) approved Imvexxy, an estradiol vaginal insert for women with moderate-to-severe sexual pain. According to a press statement, TherapeuticsMD, the drug’s manufacturer, expects Imvexxy to be available in July.

Sexual pain is a common problem after menopause, when a woman’s estrogen levels drop considerably. Estrogen is important for keeping vaginal tissue healthy and flexible. When levels decline, the vagina can shorten and narrow, with the walls becoming dry and brittle. Women may find that their vagina is less lubricated during sex. Together, these symptoms can lead to uncomfortable friction, tearing, and bleeding during vaginal intercourse.

The medical term for this situation is vaginal and vulvar atrophy (VVA). An estimated 50% of postmenopausal women experience it to some degree. Unfortunately, VVA does not improve on its own.

1 2 Next » (page 1 of 2)